LIRAOB

CompletedPhase 4

Reward Mechanisms in Obesity

Central Nervous System Effects of Liraglutide® 3.0 mg on Reward Mechanisms in Obese Patients Without Diabetes, in Relation to Food Addiction. A Randomized, Single-centre, Double-blind, Placebo Controlled Clinical Trial.

Lead sponsor

Zoltan Pataky

Asset

Liraglutide

Subcutaneous · GLP-1 agonist

Listed sites

Recruiting sites

—

Enrollment

actual

Study population

Healthy volunteers, Obesity / overweight

Key I/E criterion

•BMI 30-40

Primary endpoint

•Bold Oxygenation Level Dependent (BOLD) signal (%) in brain regions involved

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT03347890

Org study ID2017-01085

Secondary IDU1111-1194-9675Universal Trial Number

Timeline

Milestones

Study first posted2017-11-20actual

Study start2018-03-05actual

Primary completion2020-03-18actual

Study completion2020-03-30actual

Last update posted2021-04-30actual

Assets

Investigational agents

Liraglutide

Study populations

Who this study enrolls

Healthy volunteersObesity / overweight

Eligibility

Who can enroll

Minimum age18 Years

Maximum age75 Years

SexAll

Healthy volunteersAccepted

Inclusion criteria

•BMI ≥ 30 kg/m2 and < 40 kg/m2

•right-handed

•current non-smokers

•with stable body weight (<5% reported change during the previous 3 months)

Exclusion criteria

•History of any psychiatric, neurological, cardiovascular, renal or liver disease, malignancies, type 1 and type 2 diabetes mellitus

•use of centrally acting medication, glucocorticoides, insulin, orlistat

•any substance abuse

•food allergies

•deficits of smell and taste

•history of pancreatitis

•family or personal history of multiple endocrine neoplasia type 2 or familial medullary thyroid carcinoma

•pregnancy

•contraindications for fMRI

Endpoints (16)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Other (unclassified)

Glycemic / diabetes

Other clinical outcomes

Weight & body composition

Patient-reported / QoL

Cardiometabolic biomarkers

Weight & body composition

2 endpoints

Secondary/protocol endpoint

change of body weight

Time frame:16 weeks

Body weight, absolute change (kg)

change from baseline, improvement

Secondary/protocol endpoint

changes in waist circumference

Time frame:16 weeks

Waist circumference, change

change from baseline, improvement

Glycemic / diabetes

3 endpoints

Secondary/protocol endpoint

changes in fasting blood sugar

Time frame:16 weeks

Fasting glucose, change

change from baseline, improvement

LOINC 1558-6

Secondary/protocol endpoint

changes in glucagon

Time frame:16 weeks

change from baseline, improvement

Secondary/protocol endpoint

changes in insulin

Time frame:16 weeks

change from baseline, improvement

Cardiometabolic biomarkers

1 endpoint

Secondary/protocol endpoint

changes in leptin

Time frame:16 weeks

Leptin, change

change from baseline, improvement

Patient-reported / QoL

2 endpoints

Secondary/protocol endpoint

change in food addiction score

Time frame:16 weeks

change from baseline, improvement

Secondary/protocol endpoint

change in liking

Time frame:16 weeks

change from baseline, improvement

Other clinical outcomes

3 endpoints

Secondary/protocol endpoint/low confidence

change in wanting

Time frame:16 weeks

change from baseline, improvement

Secondary/protocol endpoint/low confidence

change in emotional regulation abilities

Time frame:16 weeks

change from baseline, improvement

Secondary/protocol endpoint/low confidence

BOLD in brain regions involved in the reward system

Time frame:baseline comparison

descriptive

Other (unclassified)

5 endpoints

Primary/protocol endpoint/low confidence

Change of Bold Oxygenation Level Dependent (BOLD) signal (%) in brain regions involved in the reward system

Time frame:16 weeks

percent change from baseline, descriptive

Secondary/protocol endpoint/low confidence

changes in ghrelin

Time frame:16 weeks

change from baseline, improvement

Secondary/protocol endpoint/low confidence

changes in obestatin

Time frame:16 weeks

change from baseline, descriptive

Secondary/protocol endpoint/low confidence

changes in reelin

Time frame:16 weeks

change from baseline, descriptive

Secondary/protocol endpoint/low confidence

changes in endocannabinoids

Time frame:16 weeks

change from baseline, descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.